BIOSPECIFICS TECHNOLOGIES CORP Form 8-K

November 15, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 15, 2012

# **BIOSPECIFICS TECHNOLOGIES CORP.**

(Exact name of registrant as specified in its charter)

#### **Delaware**

(State or Other Jurisdiction Of Incorporation)

#### 001-34236

(Commission File Number)

#### 11-3054851

(I.R.S. Employer Identification No.)

#### 35 Wilbur Street Lynbrook, NY 11563

(Address of Principal Executive Office) (Zip Code)

#### **516.593.7000**

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[\_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

[\_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

#### Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

### INTRODUCTORY COMMENT

Throughout this Current Report on Form 8-K, the term Company refers to BioSpecifics Technologies Corp.

#### **ITEM 8.01 OTHER EVENTS**

On November 15, 2012, the Company issued a press release announcing that its Board of Directors has authorized the repurchase of up to \$2 million of its outstanding common stock.

A press release regarding the announcement is attached hereto as Exhibit 99.1.

#### ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

99.1 Press release dated November 15, 2012

# Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 15, 2012 BIOSPECIFICS TECHNOLOGIES CORP.

(Registrant)

/s/ Thomas L. Wegman

Thomas L. Wegman President

# Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

#### **EXHIBIT INDEX**

**No.** 99.1 Press release dated November 15, 2012